{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:00:10Z","timestamp":1794355210954,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"member of the Steering Committee for the VIBRANT-HD study"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41591-025-04117-4","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:02:32Z","timestamp":1767607352000},"page":"103-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Oral splicing modulator branaplam in Huntington\u2019s disease: a phase 2 randomized controlled trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2467-6000","authenticated-orcid":false,"given":"Beth","family":"Borowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fonda","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7544-5125","authenticated-orcid":false,"given":"Mark","family":"Meadowcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier J.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Laisney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Kinhikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2716-2045","authenticated-orcid":false,"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3375-790X","authenticated-orcid":false,"given":"G. Bernhard","family":"Landwehrmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4532-766X","authenticated-orcid":false,"given":"Blair R.","family":"Leavitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"4117_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross, C. A. et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204\u2013216 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"4117_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker, F. O. Huntington\u2019s disease. Lancet 369, 218\u2013228 (2007).","journal-title":"Lancet"},{"key":"4117_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3233\/JHD-220543","volume":"11","author":"M Seefelder","year":"2022","unstructured":"Seefelder, M., Klein, F. A. C., Landwehrmeyer, B., Fern\u00e1ndez-Busnadiego, R. & Kochanek, S. Huntingtin and its partner Huntingtin-Associated Protein 40: structural and functional considerations in health and disease. J. Huntingtons Dis. 11, 227\u2013242 (2022).","journal-title":"J. Huntingtons Dis."},{"key":"4117_CR4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou, F. & Humbert, S. The biology of huntingtin. Neuron 89, 910\u2013926 (2016).","journal-title":"Neuron"},{"key":"4117_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"ME MacDonald","year":"1993","unstructured":"MacDonald, M. E. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"4117_CR6","first-page":"R115","volume":"16","author":"J Shao","year":"2007","unstructured":"Shao, J. & Diamond, M. I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Cell 16, R115\u2013R123 (2007).","journal-title":"Hum. Mol. Cell"},{"key":"4117_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross, C. A. & Tabrizi, S. J. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83\u201398 (2011).","journal-title":"Lancet Neurol."},{"key":"4117_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/toxins13070487","volume":"13","author":"A Heinz","year":"2021","unstructured":"Heinz, A., Nabariya, D. K. & Krauss, S. Huntingtin and its role in mechanisms of RNA-mediated toxicity. Toxins (Basel) 13, 487 (2021).","journal-title":"Toxins (Basel)"},{"key":"4117_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrd.2018.133","volume":"17","author":"NS Caron","year":"2018","unstructured":"Caron, N. S., Dorsey, E. R. & Hayden, M. R. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nat. Rev. Drug Discov. 17, 729\u2013750 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4117_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41573-022-00521-4","volume":"21","author":"JL Childs-Disney","year":"2022","unstructured":"Childs-Disney, J. L. et al. Targeting RNA structures with small molecules. Nat. Rev. Drug Discov. 21, 736\u2013762 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4117_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nchembio.1837","volume":"11","author":"J Palacino","year":"2015","unstructured":"Palacino, J. et al. SMN2 splice modulators enhance U1\u2013pre-mRNA association and rescue SMA mice. Nat. Chem. Biol. 11, 511\u2013517 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"4117_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34419-x","volume":"13","author":"F Krach","year":"2022","unstructured":"Krach, F. et al. An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington\u2019s disease patient neurons. Nat. Commun. 13, 6797 (2022).","journal-title":"Nat. Commun."},{"key":"4117_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28653-6","volume":"13","author":"CG Keller","year":"2022","unstructured":"Keller, C. G. et al. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat. Commun. 13, 1150 (2022).","journal-title":"Nat. Commun."},{"key":"4117_CR14","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s13311-020-00891-w","volume":"17","author":"D Dash","year":"2020","unstructured":"Dash, D. & Mestre, T. A. Therapeutic update on Huntington\u2019s disease: symptomatic treatments and emerging disease-modifying therapies. Neurotherapeutics 17, 1645\u20131659 (2020).","journal-title":"Neurotherapeutics"},{"key":"4117_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J., Ghosh, R. & Leavitt, B. R. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 101, 801\u2013819 (2019).","journal-title":"Neuron"},{"key":"4117_CR16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamaneurol.2020.0299","volume":"77","author":"BR Leavitt","year":"2020","unstructured":"Leavitt, B. R., Kordasiewicz, H. B. & Schobel, S. A. Huntingtin-lowering therapies for Huntington disease: a review of the evidence of potential benefits and risks. JAMA Neurol. 77, 764\u2013772 (2020).","journal-title":"JAMA Neurol."},{"key":"4117_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep12166","volume":"5","author":"AL Southwell","year":"2015","unstructured":"Southwell, A. L. et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci. Rep. 5, 12166 (2015).","journal-title":"Sci. Rep."},{"key":"4117_CR18","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N. Engl. J. Med. 380, 2307\u20132316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4117_CR19","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1093\/nar\/gkad259","volume":"51","author":"EW Ottesen","year":"2023","unstructured":"Ottesen, E. W. et al. Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy. Nucleic Acids Res. 51, 5948\u20135980 (2023).","journal-title":"Nucleic Acids Res."},{"key":"4117_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/01926233231180179","volume":"51","author":"D Theil","year":"2023","unstructured":"Theil, D. et al. Neurofilament light chain: a translational safety biomarker for drug-induced peripheral neurotoxicity. Toxicol. Pathol. 51, 135\u2013147 (2023).","journal-title":"Toxicol. Pathol."},{"key":"4117_CR21","doi-asserted-by":"publisher","first-page":"bio058551","DOI":"10.1242\/bio.058551","volume":"10","author":"D Theil","year":"2021","unstructured":"Theil, D. et al. Orally administered branaplam does not impact neurogenesis in juvenile mice, rats, and dogs. Biol. Open 10, bio058551 (2021).","journal-title":"Biol. Open"},{"key":"4117_CR22","unstructured":"Lozac\u2019h, F, et al. Insights into the human pharmacokinetics and metabolism of branaplam, a splicing modulator of a survival motor neuron-2 (SMN2) and huntingtin (HTT) pre-MRNAs, in infants and adults. Drug Metab. Dispos. (in the press)."},{"key":"4117_CR23","unstructured":"Faller, D. O., Faller, T., Caputo, A., Borowsky, B. & Laisney, M. Branaplam translational PK\/PD model supported key decision making in Huntington\u2019s disease. In Development Innovation Conference (2023)."},{"key":"4117_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 12, 637\u2013649 (2013).","journal-title":"Lancet Neurol."},{"key":"4117_CR25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/cdd.2015.80","volume":"22","author":"M Kaliszewski","year":"2015","unstructured":"Kaliszewski, M., Knott, A. B. & Bossy-Wetzel, E. Primary cilia and autophagic dysfunction in Huntington\u2019s disease. Cell Death Differ. 22, 1413\u20131424 (2015).","journal-title":"Cell Death Differ."},{"key":"4117_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nbd.2015.05.008","volume":"80","author":"A Karam","year":"2015","unstructured":"Karam, A. et al. A novel function of huntingtin in the cilium and retinal ciliopathy in Huntington\u2019s disease mice. Neurobiol. Dis. 80, 15\u201328 (2015).","journal-title":"Neurobiol. Dis."},{"key":"4117_CR27","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMc2300400","volume":"389","author":"P McColgan","year":"2023","unstructured":"McColgan, P. et al. Tominersen in adults with manifest Huntington\u2019s disease. N. Engl. J. Med. 389, 2203\u20132205 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4117_CR28","first-page":"A145","volume":"95","author":"T B\u00f6rstler","year":"2024","unstructured":"B\u00f6rstler, T. et al. I010 RNA splicing modulator for Huntington\u2019s disease treatment induces 1 peripheral neuropathy. J. Neurol. Neurosurg. Psychiatry 95, A145 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"4117_CR29","doi-asserted-by":"publisher","first-page":"112380","DOI":"10.1016\/j.isci.2025.112380","volume":"28","author":"F Krach","year":"2025","unstructured":"Krach, F. et al. RNA splicing modulator for Huntington's disease treatment induces peripheral neuropathy. iScience 28, 112380 (2025).","journal-title":"iScience"},{"key":"4117_CR30","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1177\/0192623312474865","volume":"41","author":"B Bolon","year":"2013","unstructured":"Bolon, B. et al. STP position paper: recommended practices for sampling and processing the nervous system (brain, spinalcord, nerve, and eye) during nonclinical general toxicity studies. Toxicol. Pathol. 41, 1028\u20131048 (2013).","journal-title":"Toxicol. Pathol."},{"key":"4117_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson, I. & Fahn, S. Huntington disease: clinical care and evaluation. Neurology 29, 1\u20133 (1979).","journal-title":"Neurology"},{"key":"4117_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Mov. Disord. 11, 136\u2013142 (1996).","journal-title":"Mov. Disord."},{"key":"4117_CR33","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","volume":"89","author":"SA Schobel","year":"2017","unstructured":"Schobel, S. A. et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology 89, 2495\u20132502 (2017).","journal-title":"Neurology"},{"key":"4117_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/1097-4679(197607)32:3<654::AID-JCLP2270320336>3.0.CO;2-Z","volume":"32","author":"CJ Golden","year":"1976","unstructured":"Golden, C. J. Identification of brain disorders by the Stroop Color and Word Test. J. Clin. Psychol. 32, 654\u2013658 (1976).","journal-title":"J. Clin. Psychol."},{"key":"4117_CR35","doi-asserted-by":"crossref","unstructured":"Smith, A. Symbol Digit Modalities Test (Western Psychological Services, 1973).","DOI":"10.1037\/t27513-000"},{"key":"4117_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04117-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04117-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04117-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:02:54Z","timestamp":1769007774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04117-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04117-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.S.M. received funding of grants from Parkinson\u2019s Foundation for acting as a Steering Committee Member, receives funding of grants from NIH, MJFF, CHDI, HSG, HDSA, Prilenia, Novartis, Roche and Springer, and receives consulting fees from Novartis and funding for leadership on the Enroll HD Oversight Committee (CHDI) and HSG Steering Committee. S.J.T. received research grant funding from the Wellcome Trust (grant no. 223082\/Z\/21\/Z), and the UK Dementia Research Institute that receives its funding from DRI Ltd, funded by the UK MRC, Alzheimer\u2019s Society and Alzheimer\u2019s Research UK, and from the CHDI Foundation and the UK Medical Research Council. Through the offices of UCL Consultants Ltd, a wholly owned subsidiary of University College London, S.J.T. has undertaken consultancy services for Alnylam Pharmaceuticals, Annexon, Ascidian Therapeutics, Arrowhead Pharmaceuticals, Atalanta Therapeutics, Design Therapeutics, F. Hoffman-La Roche, Iris Medicine, Latus Bio, Life Edit, Novartis Pharma, Pfizer, Prilenia Neurotherapeutics, PTC Therapeutics, Rgenta Therapeutics, Takeda Pharmaceuticals, UniQure Biopharma and Vertex Pharmaceuticals. In the past 12 months, University College London Hospitals NHS Foundation Trust, Professor Tabrizi\u2019s host clinical institution, received funding to run clinical trials for F. Hoffman-La Roche, Novartis Pharma, PTC Therapeutics and UniQure Biopharma. G.B.L. has provided consulting services, advisory board functions, clinical trial services and\/or lectures for Acadia Pharmaceuticals, AFFiRiS, Allergan, Alnylam, Amarin, AOP Orphan Pharmaceuticals AG, Bayer Pharma AG, Boehringer Ingelheim, CHDI Foundation, Deutsche Huntington-Hilfe, Desitin, Genentech, Genzyme, GlaxoSmithKline, F. Hoffmann-La Roche, Ipsen, ISIS Pharma (IONIS), Eli Lilly, Lundbeck, Medesis, Medivation, Medtronic, NeuraMetrix, Neurosearch Inc., Novartis, Pfizer, Prana Biotechnology, Prilenia, PTC Therapeutics, Raptor, Remix Therapeutics, Rh\u00f4ne-Poulenc Rorer, Roche Pharma AG Deutschland, Sage Therapeutics, Sanofi-Aventis, Sangamo\/Shire, Siena Biotech, Takeda, Temmler Pharma GmbH, Teva, Triplet Therapeutics, Trophos, UniQure and Wave Life Sciences. B.L. was a member of the scientific advisory board and Steering Committee for the VIBRANT-HD study. He reports paid scientific consultancies with Alnylam, GLG, Teva, Roche\/Genentech, Takeda, Triplet, Ionis, Novartis, Spark, Sintetica, Life Edit, Design, Remix Therapeutics, 3\n                      RD\n                      Rock and PTC Therapeutics and sRNAlytics (now GateHouse Bio). Dr Leavitt\u2019s Laboratory has obtained research grants from CIHR, HSC, NMIN, CHDI, Teva, ProMIS and uniQure. He is a co-founder and the current CEO of Incisive Genetics Inc. B.B., H.R., A.C., T.F., T.P., Y.S., F.L., M.M., O.J.D., M.L. and A.K. are employees and shareholders of Novartis. A.H. was an employee of Novartis at the time of the study and is now retired.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}